位置:首页 > 产品库 > CP21
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CP21
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CP21图片
规格:98%
分子量:153.2
包装与价格:
包装价格(元)
1mg询价
5mg询价
10mg询价
25mg询价

An iron chelator
货号:ajcx24902
CAS:30652-12-1
分子式:C8H11NO2
分子量:153.2
溶解度:DMF: 1 mg/ml,DMSO: 1 mg/ml,Ethanol: 10 mg/ml,Ethanol:PBS (pH 7.2) (1:4): 0.20 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

CP21 is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio.1It is active againstP. falciparumwhen used at concentrations of 10 and 100 µM.2CP21 inhibits production of prostaglandin I2induced by epinephrine, arachidonic acid , or A23187 in isolated rat aortic rings with IC50values of 1.3, 1.3, and 1.4 mM, respectively.3It inhibits glutamate-induced oxytosis, as well as decreases iodoacetic acid-induced cytotoxicity in anin vitromodel of ischemia, in HT22 mouse hippocampal cells (EC50s = 13 and 9.5 µM, respectively).4CP21 (200 mg/kg) increases the excretion of iron, but not copper, zinc, calcium, or magnesium, in rabbits.5


1.Dobbin, P.S., Hider, R.C., Hall, A.D., et al.Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: Orally active iron chelators with clinical potentialJ. Med. Chem.36(17)2448-2458(1993) 2.Heppner, D.G., Hallaway, P.E., Kontoghiorghes, G.J., et al.Antimalarial properties of orally active iron chelatorsBlood72(1)358-361(1988) 3.Jeremy, J.Y., Kontoghiorghes, G.J., Hoffbrand, A.V., et al.The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitroBiochem. J.254(1)239-244(1988) 4.Maher, P., and Kontoghiorghes, G.J.Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiproneNeurochem. Res.40(3)609-620(2015) 5.Kontoghiorghes, G.J., and Hoffbrand, A.V.Orally active α-ketohydroxy pyridine iron chelators intended for clinical use: In vivo studies in rabbitsBr. J. Haematol.62(4)607-613(1986)

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024